Non small Cell Lung cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer research hub

A Phase 2 Randomized Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

This study looks at a new drug combination for advanced non-small cell lung cancer. Researchers are testing whether adding a modern immunotherapy medicine called relatlimab to standard immunotherapy and chemotherapy works better and is safe for adults who have not yet had treatment for their advanced cancer.